FibroGen, Inc., headquartered in San Francisco, California, is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for serious unmet medical needs. Since its founding in 1993, the company has built a diversified portfolio encompassing small molecules and biologics that address anemia, fibrotic diseases and oncology.
The company’s lead product, roxadustat, is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to treat anemia in chronic kidney disease. Roxadustat has received regulatory approval in China, Japan and several other markets, and is being developed globally through strategic partnerships with Astellas Pharma and AstraZeneca. In addition to roxadustat, FibroGen is advancing pamrevlumab, a monoclonal antibody in late-stage trials for idiopathic pulmonary fibrosis and other fibrotic disorders, as well as early-stage oncology assets aimed at modifying the tumor microenvironment.
FibroGen operates research and development centers across North America, Europe and Asia, leveraging both in-house expertise and external collaborations to drive clinical progress. The company’s global footprint enables efficient regulatory engagement and commercialization in multiple jurisdictions, from China’s rapidly growing pharmaceutical market to established regulatory regions such as the United States and Europe.
Under the leadership of President and Chief Executive Officer Tom Neff, FibroGen emphasizes rigorous science and strategic partnerships to accelerate its pipeline. The management team combines biotech innovation with industry experience, steering the company through clinical milestones and regulatory approvals while seeking to bring transformative medicines to patients worldwide.
AI Generated. May Contain Errors.
